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Abstract
Objective—Demonstrate rapid initiation of co-formulated treatment during acute HIV infection 
(AHI) is feasible and efficacious.
Design—Prospective, single-arm open label study of once daily emtricitabine/tenofovir/efavirenz 
initiated during AHI.
Methods—We provide final data through week 96-week of emtricitabine/tenofovir/efavirenz 
initiated during AHI. The primary endpoint was the proportion of responders with HIV RNA <200 
copies/mL by week 24. We examined time-to-viral-suppression, retention and CD8 cell activation 
through week 96 in relation to baseline characteristics.
Results—Between January 2005 and December 2011, 92 AHI participants enrolled. Most 
participants (78%) were MSM, and 42% were young MSM (18–25 years of age). Two participants 
withdrew leaving 90 patients for analysis. Eighty-one (90%) remained on therapy and achieved 
viral suppression to <200 copies/mL by week 24, and 71 (79%) to <50 copies/mL at week 48. The 
median time from ART initiation to suppression <200 copies/mL was 65 days (range 7–523) and 
to <50 copies/mL was 105 days (range 14–523). The frequency of CD8 activation declined from a 
median of 67% to 16% through week 96. Retention on study was maintained in 92% of 
participants at week 48 and in 83% through week 96. Among 75 participants retained through 
Corresponding Author: Cynthia L. Gay, 130 Mason Farm Road, CB #7030, Suite 2112 Bioinformatics Building, Chapel Hill, NC 
27599-7030. cynthia_gay@med.unc.edu. 
Role of Authors: Study design was done by C.L.G, J.D.K., D.M.M., C.B.H., G.F., J.J.E.; data generation/assay performance was done 
by C.L.G., S.W., A.B.C., J.D.K., K.S.M., M.M, J.S., S.A.F., G.F.; drafting of the paper was done by C.L.G., J.D.K., S.A.F., M.M., 
D.M.M., G.F., J.J.E.
Potential Financial Conflicts of Interest: S.W., A.C., J.K., J.S., K.M., M.M., S.F., G.F. - No conflicts.
HHS Public Access
Author manuscript
AIDS. Author manuscript; available in PMC 2017 November 28.
Published in final edited form as:













week 96, 92% were suppressed to <50 copies/mL. Among 39 young MSM, 79% completed a 
week 96 visit and 67% were suppressed at week 96.
Conclusions—ART during AHI resulted in rapid and sustained viral suppression with high rates 
of retention in care and on ART in this cohort including a large proportion of young MSM.
Keywords
Acute HIV infection; NNRTIs; antiretroviral therapy; viral dynamics; young men who have sex 
with men; immune activation
Introduction
In 2013, HIV treatment guidelines were revised to recommend initiation of antiretroviral 
therapy (ART) during acute HIV infection (AHI) [1], including immediate treatment 
initiation modified, if indicated, by a HIV drug resistance genotype [2]. The shift toward 
treatment during early infection and AHI drew from accumulating data on the potential 
benefits of early ART including preservation of immune function [3, 4], decreased HIV 
RNA set point [5–7], reduced size of the latent HIV pool [8–11], and limited viral diversity 
due to the suppression of viral mutations [12, 13]. Reducing the risk of onward transmission 
of HIV to sex partners is a likely additional benefit of early ART based on evidence of the 
preventive efficacy of treatment in serodiscordant couples [14] and the strong association 
between transmission risk and HIV RNA levels in plasma and genital secretions, typically 
very high during the acute period [15, 16]. Finally, recent studies have demonstrated a 
clinical benefit of earlier versus delayed initiation of ART [17]. Accordingly, guidelines have 
shifted toward recommending ART for all patients, including those with AHI.
Despite the evolution in guidelines on when to start ART, data on what specific ART drugs 
should be initiated during AHI remain limited. Updated guidelines continue to recommend a 
protease inhibitor (PI)-based regimen if treatment is started prior to ARV drug resistance 
testing, based on low rates of transmitted resistance to PIs and a higher barrier to PI 
resistance. However, PI-based therapy requires multiple pills with adherence implications, 
the potential for decreased tolerability and drug-drug interactions.
We previously reported interim results from a study showing that co-formulated, once-daily 
emtricitabine/tenofovir/efavirenz (FTC/TDF/EFV) initiated during AHI achieved rapid and 
sustained HIV suppression despite initial high viremia [18]. In our interim results with 61 
AHI participants, 92% were suppressed to <200 copies/mL by week 24, and 85% with the 
potential to reach week 48 remained suppressed. We demonstrated that immediate initiation 
of ART prior to baseline HIV genotype results did not prevent viral suppression in the small 
number of participants with baseline mutations conferring resistance to the study regimen, 
following the assessment of ART resistance by an HIV genotype to guide changes to the 
regimen. Finally, we observed a trend toward a shorter time to viral suppression among 
participants treated during AHI in comparison with a historical cohort of patients who 
started similar ART with established infection, despite higher pre-ART viral loads among 
the acutely infected participants [18].
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We now provide additional data on responses to a co-formulated single tablet, once-daily, 
NNRTI-based ART regimen initiated in 92 individuals with AHI through 96 weeks of 
follow-up. As in the prior report, our primary goal was to demonstrate that rapid linkage of 
acutely-infected individuals to simple, effective ART would facilitate prompt and sustained 
HIV-1 suppression. Although fixed-dose combination FDC FTC/TDF/EFV is no longer a 
recommended first line regimen in the United States [2], our findings inform decisions on 
the provision of ART for acutely infected individuals related to pill burden, postponement of 
treatment for results of resistance testing, the risk of virologic failure and de novo resistance, 
as well as adherence and retention, particularly among young men who have sex with men 
(MSM), a group that comprises a majority of acutely infected individuals in the Southeastern 
United States [19, 20].
Methods
The study population included individuals ≥18 years of age referred from the North Carolina 
(NC) Screening and Tracing Active Transmission (STAT) Program, a statewide screening 
program for AHI in publicly funded testing sites [21]. Additional cases are identified 
through HIV testing performed at primary care testing sites and referred and/or reported to 
the NC Department of Health and Human Services (DHHS). Following identification of 
suspected or confirmed acute HIV cases through rapid notification from the STAT program 
to the NC DHHS or from primary care sites, specially trained NC DHHS Disease 
Intervention Specialists (DIS) ensure notification and make referrals to HIV care within 72 
hours. All acutely infected individuals referred to UNC and Duke and meeting eligibility 
criteria were offered the opportunity to enroll on the study.
This study was a dual-center, single-arm open-label study of the safety and efficacy of once 
daily, FTC/TDF/EFZ administered to participants with AHI as previously described [18]. 
Prior to October 25, 2006, participants received study treatment as a two-tablet regimen of 
fixed dose combination FDC FTC/TDF (Truvada) and Efavirenz (Sustiva) both taken once 
daily, while those enrolled afterwards were administered FDC FTC/TDF/EFZ (Atripla). AHI 
was defined as a negative or indeterminate enzyme immunoassay (EIA) or a negative HIV 
RNA test within 30 days of enrollment plus a reproducibly detectable HIV by amplification 
methods. AHI diagnosis date was defined as the date of the first test detecting the presence 
of HIV. The estimated-date-of-infection was calculated as 14 days prior to onset of 
symptoms consistent with acute retroviral syndrome [22].
Exclusion criteria were minimal and included the following: pregnancy, breastfeeding, 
inability to commit to acceptable contraceptive methods to prevent pregnancy, recent history 
of acute hepatitis, severe acute illness, incarceration or recent/current administration of 
experimental therapy, immune-modulating agents or contraindicated medications. Baseline 
resistance testing was performed on all participants at enrollment, but ART initiation was not 
delayed for receipt of genotype results. Baseline resistance was assessed as the presence of 
any of the surveillance drug resistance mutations listed by the World Health Organization 
[23]. In most cases, participants were screened, enrolled and started study treatment on day 
of their initial evaluation for AHI. Participants were evaluated on study at weeks 1, 2, 4, 8, 
12, 16, 24, 36, 48, 60, 72, 84 and 96 and received $25.00 per study visit as reimbursement.
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HIV RNA was measured using the Roche Amplicor Monitor ultrasensitive assay, version 1.5 
with a 50 copies/mL lower limit of detection prior to December 2008, and with the Abbott 
RealTime HIV-1 assay with a 40 copies/mL lower limit of detection thereafter. The level of 
circulating CD8+HLA-DR+CD38+ T cells was measured in a subset of participants through 
June 2010 in fresh blood samples collected in EDTA tubes by flow-cytometry at enrollment, 
24 weeks after starting ART, and every six months thereafter through week 96. Circulating 
activated CD8+ cells were identified using the following panel of antibodies: aCD3-PerCP; 
aCD8-FITC; aHLA-DR-APC: and aCD38-PE. The samples were acquired using a 4-color 
Calibur flow cytometer instrument (Becton Dickinson, San Jose, CA). The study was 
approved by the University of North Carolina at Chapel Hill (UNC) and Duke University 
Institutional Review Boards. All participants provided written informed consent.
The distribution of demographic and clinical characteristics was examined for all 
participants. The demographics of interest included age, sexual risk group, and race/
ethnicity. Clinical characteristics included STD diagnosis within 8 weeks of acute HIV 
diagnosis, serostatus at ART initiation, duration from estimated-date-of-infection until 
treatment, and viral loads (copies/mL) and CD4 cell counts (cells/mm3) throughout the 
study. We defined virologic failure as failure to suppress to <200 copies/mL by week 24 [23] 
or HIV RNA >50 copies/mL at week 48.
We updated our analysis of time to viral suppression in relation to baseline characteristics 
with the 89 AHI participants who remained on treatment at designated time points. Time to 
viral suppression was defined as the time (days) to HIV RNA <50 copies/mL after ART 
initiation. As before, parameters included baseline CD8+ cell activation, duration from 
estimated-date-of-infection until treatment, and baseline HIV RNA level. Each parameter 
was dichotomized into those less than or equal to the median value and those above the 
median value. Participants were censored if they stopped treatment, were lost to follow-up or 
had their last visit before week 24. Log-rank tests were used to test differences in 
suppression times between exposure groups. Multivariable proportional hazards regression 
was used to estimate hazard ratios for the association between baseline CD8+ cell activation 
and time to viral suppression. Potential confounders included baseline HIV RNA, CD4 cell 
count and age. Confounders that resulted in a 10% or greater change in estimate were 
retained in the model. Our final model included log transformed baseline HIV RNA and 
CD4 cell count.
The frequency of CD38+HLA-DR+ CD8+cells measured by flow cytometry was compared 
between AHI participants on treatment and a seronegative cohort using two sample T-test 
statistics. To determine the clinical characteristics associated with baseline frequency of 
activated CD8+ cells, we performed linear tests for trend. We used linear regression to assess 
for the association between baseline CD4 cell count and the binary indicator of CD8 
activation at week 96 (above and below the median) by mean and median CD4 at baseline. 
We also performed bivariate analysis to assess for associations between demographic and 
clinical characteristics and retention on study at or after week 48. We used the Fisher’s exact 
test for categorical variables and the Kruskal Wallis test for continuous variables. All 
statistical analyses were performed with SAS version 9.4 (SAS Institute; Cary, N.C.).
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Between January 2005 and December 2011, 92 acutely-infected participants enrolled in the 
study and began therapy. The median age of participants at enrollment was 27 years (range 
18–66), with 42 participants (46%) aged ≤ 25 years (Table 1). Most participants (78%) were 
MSM, including 39 MSM (42%) between 18 and 25 years of age. Over half (59%) of AHI 
participants were African American. The median initial HIV RNA level for AHI participants 
was 614,898 copies/mL (range 615–29,807,640), and the median observed peak HIV RNA 
level was 746,103 copies/mL (range 5,470–160,000,000); this analysis included pre-
enrollment HIV RNA levels performed on samples obtained on the initial HIV testing date. 
The median HIV RNA level at enrollment on study was 169,365 copies/mL. Using an 
estimated date of infection [22, 24], the median time from HIV acquisition to the date of 
ART initiation was 42 days (range 21–140). The median baseline CD4 cell count at 
enrollment was 487 cells/mm3 (range 13–1316) and increased to 638 cells/mm3 at week 24, 
700 cells/mm3 at week 48 and 765 cells/mm3 at week 96 (Table 1). Two participants 
initiated study treatment but withdrew at 4 and 13 days following enrollment due to baseline 
resistance to efavirenz and to join an alternative treatment study. They were excluded from 
further analysis except for baseline resistance.
Eighty-one (90%) of the 90 participants suppressed to <200 copies/mL prior to or at week 
24. Among the 9 (10%) participants who met criteria for treatment failure at week 24, 3 
(3%) were lost to follow-up prior to week 24, 3 (3%) had ongoing viral decline with HIV 
RNA <200 copies/mL at week 36, and one had viremia >200 copies/mL through week 36 
but suppressed to <50 copies/mL at week 60 (missed week 48) and thereafter. One 
participant had an isolated low viral load at week 24 preceded and followed by viral 
suppression, and the final participant stopped study treatment within 2 weeks due to rash 
attributed to study treatment and was followed off ART until after week 48 per participant 
preference. No participant had sustained plasma HIV RNA rebound on therapy.
At week 48, 71 (79%) participants had an HIV RNA <50 copies/mL. Of the 19 (21%) 
participants who did not have documented suppression at week 48, 7 (8%) had detectable 
plasma HIV RNA preceded and followed by durable viral suppression, 5 (6%) were lost to 
follow-up, 4 (4%) were off ART, 2 (2%) had HIV RNA <50 before and after week 48 but 
missed the week 48 visit, and 1 (1%) had persistent viremia on treatment at week 48. The 
participant with viremia at week 48 had baseline NNRTI resistance and missed weeks 16 
through 36, but suppressed to <50 copies/mL on an integrase-based ART regimen initiated 
after week 48. Among the 4 participants who remained on study but off ART at week 48, 
three later suppressed to <50 copies/mL after re-initiation of ART. All participants who 
remained on study at week 48 and chose to continue or restart ART maintained or re-
established virologic suppression.
The percentage of participants retained on the study and ART was high through week 96 
(Figure 1). Overall at week 24, 87 (97%) participants were retained on the study; 77 (86%) 
remained on initial therapy with FDC FTC/TDF/EFZ, 9 (10%) were on an alternative 
therapy, and one (1%) participant was off therapy (Figure 2). Three participants were lost to 
follow-up. At week 48, 85 (94%) participants were retained in care and on the study with 74 
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(82%) still on FDC FTC/TDF/EFZ, 7 (8%) on alternative therapy, and 4 (4%) off therapy; 5 
(6%) were lost to follow-up. Overall, 78 (85%) participants completed a study visit at week 
72 or after (Figure 1). Retention in the study at week 48 or after was not associated with age, 
risk group, race, ethnicity, county at AHI diagnosis, history of substance use or time to viral 
suppression.
Seventy-five (83%) of 90 participants completed a week 96 study visit, with the remaining 
15 (17%) lost to follow-up. At week 96, 65 (72%) participants remained on the initial study 
regimen and 60 (92%) were suppressed to <50 copies/mL (Figure 2). Among participants 
with viremia at week 96, two were <1000 copies/mL, two had viral loads of 4678 and 
12,964 copies/mL and the one participant off ART was viremic to 329,855 copies/mL. All 
nine participants on an alternative regimen at week 96 were suppressed to <50 copies/mL. 
Only one participant acquired resistance while on study treatment with a new K103N 
mutation on repeat genotype testing not seen at baseline and in the setting of viremia and 
self-report of non-adherence.
Given low reported rates of ART administration, viral suppression and retention in care 
among young MSM [25–27] and their prevalence among AHI cases, we assessed viral 
suppression and retention among participants between 18 and 25 years of age who self-
reported as MSM. Among 37 young MSM, 35 (95%), 33 (89%) and 31 (84%) completed a 
study visit at week 24, 48 and 96, respectively. In addition, 31 (84%), 25 (68%) and 26 
(70%) of young MSM were suppressed to <50 copies/mL at weeks 24, 48 and 96, 
respectively. Overall, loss to follow-up at week 96 was similar among young MSM at 16% 
(n=6) compared to 17% (n=9) (Chi-square p=0.92) among all other AHI participants on the 
study.
The median time from ART initiation to viral suppression <200 copies/mL was 65 days 
(range 7–523) and to <50 copies/mL was 105 days (range 14–523) (Figure 3). The median 
time to suppression among just young MSM (ages 18 to 25) was 54 days (range 7 to 171). In 
our interim analysis, higher viremia was associated with a longer time to suppression. 
However, repeat analysis with a larger sample size indicated that higher HIV RNA levels at 
ART initiation (Log-rank p=0.20), time of estimated date of infection to the initiation of 
ART (Log rank p=0.36), and baseline CD8+ cell activation (Log-rank p=0.29) were not 
associated with a longer time to viral suppression.
Of the 92 patients enrolled in the study, two (2%) withdrew due to transmitted resistance 
(both were subsequently enrolled in a different acute HIV infection study), and 15 (16%) 
changed to an alternative treatment while remaining in the study. Reasons for changing 
initial study treatment included detection of transmitted resistance to one of more of the 
drugs contained in the regimen (n=10; 11%), side effects (n=5; 5%) attributed to efavirenz, 
and non-adherence (n=2; 2%). Seventeen (18%) of the initial 92 acutely-infected 
participants had baseline resistance testing showing at least one of the surveillance drug 
resistance mutations [23]. Among these, 10 (11%) participants had baseline resistance to the 
NNRTI component of the study treatment regimen (K103N/S, 181C), two of whom 
withdrew to start a different ART regimen on another study (as stated above). Among the 
eight participants with baseline NNRTI resistance who remained on study, four (86%) 
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suppressed to <200 copies/mL by week 24, and remained suppressed to <50 copies/mL at 
weeks 48 and 96, following rapid genotype guided change in the ART regimen. Three others 
interrupted therapy and eventually restarted alternative ART and had HIV RNA <50 c/mL at 
week 96. One participant with baseline resistance suppressed to <50 copies/mL by week 16 
on an alternate ART regimen, but later had confirmed low level viremia with self-reported 
non-adherence and remained off ART after week 36.
The median frequency of CD8+CD38+HLADR+ T-cells among AHI participants at baseline 
was 67% (range 23–95) (Figure 4), a level significantly higher than among the seronegative 
cohort (p=<0.0001). The frequency of immune activation continued to decline over time to a 
median of 16% (range 9–66%) at week 96, although the rate of decline slowed considerably 
after week 24 (Figure 4). Both participants with much higher levels of immune activation of 
62% at week 48 and 66% at week 96, as shown by open circles in Figure 4, were off ART 
and viremic at 54,721 copies/mL and 329,855 copies/mL, respectively. Baseline CD4 counts 
were inversely associated with activated CD8+ cells at baseline (p<0.01) and log-
transformed initial HIV RNA levels were marginally associated with activated CD8+ cells at 
baseline (p=0.07). However, frequency of activated CD8+ cells above the median of 67% 
was not significantly associated with time to viral suppression (adjusted HR = 0.92; 95% CI 
0.55,1.56).
Among 9 participants with viral suppression and immune activation data at week 96, 
baseline CD4 cell count was not associated with CD8+ activation at week 96.
Discussion
In this 96-week, prospective, open-label study of FDC FTC/TDF/EFZ initiated during AHI, 
most participants who remained on treatment achieved viral suppression <200 copies/mL by 
week 24 and <50 copies/mL by week 48 (90% and 79% respectively). Viral suppression 
rates in our analysis are comparable with those from large studies of ART efficacy 
(including FDC FTC/TDF/EFZ) among patients with established HIV. Of the 90 participants 
who remained on study, 75 (83%) were retained through week 96, most of whom remained 
on FDC FTC/TDF/EFZ [n=65 (72%)]. Of these, 60/65 (92%) had HIV RNA <50 copies/mL 
at week 96. Further, most participants completing a week 96 visit, regardless of their ART 
regimen, were suppressed to <50 copies/mL. Only one participant was off therapy at the end 
of the study and only one participant had virologic failure with emergence of resistance 
(K103N).
Our findings indicate that immediate ART in the setting of AHI is feasible, effective and 
allows for retention in care and durable viral suppression. Essentially all acutely infected 
individuals referred to UNC and Duke University were offered the opportunity to enroll on 
the study, and none were excluded from study participation due to lack of stable 
transportation or active substance abuse. Despite the minimal exclusion criteria, viral 
suppression rates remained high during the two years of follow-up among our AHI 
participants, which included a large proportion of young MSM. Young MSM remain the 
most heavily affected population with newly diagnosed HIV infection in the United States, 
and both incidence and prevalence continue to increase in this population. Our findings 
GAY et al. Page 7













indicate that more widespread programs targeting rapid and facilitated linkage to care and 
treatment for acutely infected young MSM are needed, feasible and effective. Prior 
published rates of viral suppression among HIV-infected African American youth [25] and 
young MSM [26] have ranged much lower from 18 to 27%, compared with the 64–79% 
suppression rates among young MSM observed in our population.
Treatment success may have been facilitated by the reimbursement ($25.00) provided to our 
participants at each study visit, and assistance with transportation to study visits for some 
participants likely enhanced retention in care. Despite these incentives, we believe the 
minimal exclusion criteria among newly diagnosed individuals in our study (including 
young MSM) make our data relevant to the immediate initiation of ART in acutely infected 
individuals in all clinical settings, for the benefit of both individuals and the public health. 
Treatment failure on our study, defined as an HIV RNA level >50 copies/mL or missing data 
at 48 or 96 weeks, was predominantly driven by lost to follow-up and not by overt virologic 
failure suggesting poor adherence. However, given the potential impact of reimbursement on 
retention and thus suppression in our study, intensive efforts to keep patients in care will be 
needed to achieve the UNAIDS goal of suppression rates of 90% for patients started on 
therapy [28–30].
FDC FTC/TDF/EFZ was well-tolerated with the most common reason for ART change the 
presence of baseline resistance to the NNRTI component. A previous study found a high 
prevalence (19%) of transmitted NNRTI resistance among a cohort of acutely infected 
individuals diagnosed in the Southeastern US, a rate higher than that which has been 
reported among patients with established HIV infection [31]. The 10% prevalence of 
transmitted NNRTI resistance in our study was lower, a finding that may be due to decreased 
onward transmission of NNRTI-resistant variants. Our data support the approach of prompt 
initiation of an NNRTI-based regimen in patients with AHI with rapid transition of those 
found to have transmitted NNRTI resistance to alternative regimens. Given the accumulating 
evidence of the benefits of earlier treatment [17] and the impact of immune activation on 
morbidity among HIV patients, our data showing substantial declines in immune activation 
through week 96 further supports earlier treatment intervention.
Although FDC FTC/TDF/EFZ is no longer a recommended first line regimen by US and 
European guidelines, internationally it remains the first-line regimen per recommendations 
of the World Health Organization (WHO) [32]. Our data also support the strategy of 
initiating a simple one-pill, once-daily integrase inhibitor-based regimen as opposed to a 
multiple-tablet PI-based ART while awaiting HIV genotype results. Taken together, these 
data should encourage clinics and providers to expeditiously link acutely infected patients to 
care and rapidly initiate ART.
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Retention among AHI Participants. The figure shows the percentage of participants started 
on ART during AHI who attended study visits from baseline (week 0) through week 96.
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Figure 2. Proportion of participants suppressed, unsuppressed and lost to follow-up on study
LTFU = loss to follow-up
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Cumulative incidence of viral load supression <50 copies/mL among study participants 
initiating ART during AHI, by viral load measurement at ART initiation.
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Distribution of immune activation among study participants initiating ART during AHI 
through week 96 and a seronegative comparison group. The center lines of the boxplots 
represent the median and the left and right sides of the boxes denote the 25th and 75th 
percentiles, or interquartile ranges (IQR). The diamond shape represents the mean. The 
horizontal bars extend to the most extreme data points within 1.5 times the IQR. The circles 
beyond the lines represent outlying values.
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Table 1
Demographic and clinical characteristics of acutely infected participants starting ART
PHI02
N=92
N or Median % or Range
Age (years) 27 18 – 66
Sexual risk groups
Female 11 12%
Heterosexual Male 9 10%
MSM 72 78%
Race/ethnicity
White, Non-Hispanic 36 39%
White, Hispanic 2 2%
African American 54 59%
Asian 0 0%
Symptoms
STD <8 weeks prior to diagnosis 14 15%
Seronegative at ART start 63 68 %
Viral load (copies/mL)
Initial 614,898 615 – 29,807,640
Peak observeda 746,103 5,470 – 160,000,000
CD4 cell count (cells/mm3)
Nadir 400 13 – 1235
Baseline 487 13 – 1316
Week 24b 638 143 – 1429
Week 48b 700 167 – 1726
Week 96b 765 198 – 1449
Time, days
Infection to ART 42 21– 140
Diagnosis to ART start 19 4 – 41
ART start to viral load <50 copies/mLc 105 14 – 523
ART start to viral load <200 copies/mLc 65 7 – 523
a
HIV RNA levels prior to study enrollment were included when available.
b
Includes CD4 cell counts for study participants who attended study visits for the designated week.
c
91 participants who achieved viral load <50 and <200 copies/mL included.
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